Analyseartikel • Dec 20

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...

Seeking Alpha • Aug 09

Invitae: Revenue Troubles Build

Summary Invitae's shares have plummeted as the company slashed its growth forecast to avoid bankruptcy. Revenue for Q2 was slightly above estimates but down 12% YoY, and analyst revenue estimates have significantly declined. The company's financials remain concerning, with ongoing losses and cash burn, potentially necessitating a capital raise. Read the full article on Seeking Alpha

Seeking Alpha • Jul 16

Invitae Is Treading In Competitive Waters

Summary Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for these exits, revenue grew 10% YoY. The company has significant debt, issued through convertible senior notes due in 2024 and 2028, totaling $1.5 billion, which could limit its ability to innovate, invest, and stay competitive in the genetic testing industry. In an industry as competitive as genetic testing, Invitae's financial vulnerabilities could significantly impact their ability to stay ahead. Read the full article on Seeking Alpha

Analyseartikel • Jun 26

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation's ( NYSE:NVTA ) price-to-sales (or "P/S") ratio of 0.6x may look like a pretty appealing investment...

Seeking Alpha • Jan 19

Invitae: What Happened At The JP Morgan Health Conference

Summary NVTA Q4 cash balance remained flat year-over-year at $555M, with 2022 revenue declining by $4M to $122M. Shares appreciated 25% after last week's Q4 purview on optimism over management's ability to trim operating costs, which would provide NVTA with sufficient runway to execute its long-term strategy. Any further appreciation in the stock price will likely be met by aggressive share issuance, given the need to bolster the company's balance sheet. Investment Thesis Last week, JP Morgan hosted their 41st annual health conference in San Francisco. This year, the meeting focused on topics such as the role of technology in healthcare, physician shortages, and how to navigate healthcare reform best, incorporating presentations from healthcare start-ups to well-established industry leaders. One of the highlights was a presentation by Invitae (NVTA), a leading genetic testing company in the Cancer Risk Screening market. Present at the meeting were CEO Kenneth Knight, CFO Roxi Wen, and CMO Dr. Bob Nassbaum, with Julia Qin, a healthcare analyst at JP Morgan (who has a sell rating on the stock), serving as moderator. The management team shared their vision for the company and an overview of the top revenue drivers and pipeline opportunities. Here are a few highlights from the presentation. The Company's Vision Kenneth Knight started the presentation with an overview of NVTA's mission, vision, and values, focusing on expanding genetic testing into mainstream medicine while enhancing healthcare equality and access. He believes that current genetic testing practice is primarily fragmented and siloed by disease state and that further integration of genetic testing is required to accelerate the impact of this testing in healthcare. To that end, NVTA has been focusing on building a comprehensive molecular diagnostic portfolio supported by solid IT infrastructure and partnerships with leading Electronic Health Record system providers, including Wisconsin-based industry leader, Epic Systems, leveraging recent advancements in DNA sequencing, making its business model economically feasible. I share NVTA's vision, and I believe that the natural trajectory of medicine is toward greater integration of genomics testing and data analysis to drive more efficient treatment decisions and improve patient outcomes. However, I see significant impediments in the short run and a notable first-mover disadvantage as NVTA and many pioneers sharing its mission spent hundreds of millions on awareness campaigns, lobbying, and education only for others to reap the benefits. The market entry barriers are shallow, and I believe that NVTA needs to have a moat to protect its market share. We are yet to see significant changes in physician workflow to incorporate genetic testing. Even on staffing, I don't see a meaningful response by healthcare providers to increase genetic counselors. The CEO proceeded to brief the audience on the company's portfolio and pipeline, as discussed in more detail below. Market Position NVTA is the market leader in the Hereditary Cancer Risk testing market, with over three million patients tested up-to-date. Cancer Risk Assessments are genetic tests that measure the risk of developing cancer-based on genetic makeup. For example, patients with a BRCA mutation have about a 40% to 85% probability of developing breast cancer. The market grew significantly after a US Supreme Court ruling rendering Myriad Genetics' (MYGN) patents over BRCA genes (and any naturally-occurring biological substance) invalid in 2013. Subsequently, some businesses, notably 23andme(ME), rolled out their tests relying on a direct-to-consumer model, while others, like NVTA, sought clearance to sell Hereditary Risk test as a Laboratory Developed Test "LDT" from the Center for Medicare and Medicaid Services CMS. Although the marketing pitch of Hereditary Cancer Risk assessment has the elements of success, including the urgency element and desire to know one's genetic predisposition to develop cancer, most of the industry's revenue is derived from patients who already have cancer whose care providers are interested the cancer prognosis; whether their DNA was a factor of them developing the diseases. One reason for the low market share of DTC market participants is the lack of awareness of the value of genetic counseling among the general population and the fact that most people are afraid of what they might discover from their genetic test, or they simply choose not to know for fear of worrying themselves too much. One can't also ignore the Labor shortage in the genetic counselors market. Another reason is the challenging reimbursement landscape and the lack of unified guidelines from key opinion leaders. The CMS' reimbursement decisions carry significant weight in the market, and many private insurers follow their choices when designing their coverage policies. For now, the CMS and major health insurance companies are covering hereditary risk screening for patients with cancer. However, the full-scale population-wide screening that NVTA envisions remains years away. In previous articles, I talked about cases where women underwent unnecessary mastectomies and oophorectomies because they received a notification that they were at increased risk of developing breast or ovarian cancer from specific genetic variants in their DNA before finding out that what was believed a risk actually had no clinical implications at all. The FDA's warning about the accuracy of molecular genetic testing last year is one factor to consider when assessing NVTA's potential Strategically, companies such as Exact Sciences (EXAS) and Guardant Health (GH) have a more solid regulatory foundation than NVTA, with the majority of their income coming from FDA-approved tests, contrary to NVTA, whose CILIA-waved tests are only regulated by the CMS. On the competitiveness front, one should note that the correlations between gene mutations and disease risk are unpatentable, leaving little competitive moat or barriers to new entrants. It has become expected for gene testing companies to share their findings regarding the impact of genetic makeup on health with the public, driven by patient advocacy groups and key opinion leaders, especially after the Supreme Court decision that invalidated the patentability of these findings. NVTA is a major contributor to ClinVar, the US national genetic library. Given these dynamics, one can't help but question the company's willingness to provide its tests without monetary compensation for the sake of amassing genetic data, an endeavor that underpins its historically negative gross margins in the five years spanning 2012 - 2017. Data by YCharts

Seeking Alpha • Jan 09

Invitae guides Q4 revenue above estimates

Invitae (NYSE:NVTA) expects prelim Q4 revenue of ~$122M vs. analysts estimates of $121.41M. Revenue is expected to fall from $126M a year ago due to the exited businesses and geographies. The medical genetics company generated revenue of approximately $516M (consensus: $515.60M) in 2022, or about a 12% increase from $460M in 2021. Total active healthcare provider accounts grew 8% from 2021 to ~20,000, while active pharma and commercial partnerships grew to ~230 (+29%). As of December 31, 2022, cash, cash equivalents, restricted cash and marketable securities were greater than $555M. Invitae (NVTA) will report its full financial results and other metrics during its fourth quarter and year-end 2022 conference call in late February. NVTA shares were up around 2% shortly before 11AM ET.

Seeking Alpha • Dec 15

Invitae Likely Hasn't Reached The Bottom Yet

Summary NVTA's ambitious goal of creating a genomic data network where it resides at its center is crushed by the realities of a fragmented nascent market still finding its footing. Market conditions are unlikely to improve anytime soon, and NVTA is finding it tough to rely on the equity market to fund operations. Uncertainty surrounds the company's reorganization plan. Commercial obligations tied to intensive R&D activities constrain the company's financial flexibility and ability to respond to changing market conditions. NVTA's debt, while carrying a low-interest rate, is big enough to strain its finances. Investment Thesis In September, I called attention to a tactical buy opportunity in Invitae (NVTA), advising investors to consider the stock's potential upside highlighting Q3 results as a catalyst likely to offer clarity over management's restructuring plan announced in July. I also stressed the tactical nature of this trade opportunity, drawing attention to the company's medium-term and long-term concerns. In the following weeks after the report's publication, NVTA's shares spiked to a high of $3.6 per share, representing nearly a 50% increase, hitting our initial price targets. Once the investment thesis played out, and the window of opportunity closed, I published a Sell rating report in November underscoring NVTA's structural weakness, outlining several key reasons for a bearish stance. Since then, shares declined substantially lower, reaching a low of $2.3 last week as the market digests the challenges previously masked by the initial bullish rally. I think it is only a matter of time before further disappointments emerge and trigger further share-price declines. Pivoting to profitability will likely require painful asset write-downs and costly investments, which will be challenging to fund given the uncertain timeline for commercial launches and increasing competition in the genetic-testing space. A considerable portion of NVTA's proforma cash burn is tied to mandatory spending, including obligations tied to its R&D projects incorporating multiple clinical trials with thousands of patients who trust NVTA to continue funding the programs where they have enrolled. Management also expects $170 million in restructuring costs, from severance payments to facility closures, employee relocations, and voluntary terminations, in addition to the tens of millions of dollars it has already spent in the past two quarters. The company barely has enough money to get through the next 12 months. Adding insult to injury is the rollout of Illumina's (ILMN) new gene sequencing platform, NovaSeq X, priced at $1.7 million, which is expected to cut turnaround times, a critical market differentiator in the molecular diagnostic space. This is ILMN's first new product launch in five years, increasing the pressure on existing competitors in the molecular diagnostic space to ramp up capital spending. This is why, despite its liquidity challenges, NVTA is allocating $200 million for CAPEX in 2023. For these reasons, I am reiterating NVTA's sell rating. Market Position Before acquiring ArcherDx in October 2020, NVTA's primary business was focused on predictive genomics, which remains its primary source of income to this day. For those new to NVTA, here is an example of a typical predictive diagnostic test sale cycle. After a liquid biopsy sample (saliva, blood, etc.) is collected from the patient, NVTA analyses the sample using a Next Generation Sequencing "NGS" device before saving the patient's DNA sequence data on its servers. The company then runs its proprietary algorithm to detect genetic variants associated with increased cancer risk. The report is shared with the patient's healthcare provider via a chatbot (last week, NVTA settled with OptraHealth over this chatbot after the latter counter-sued NVTA's initial claim over an underlying patent. Under the terms of the settlement, NVTA now pays license fees for the chatbot from OptraHealth. At least management was serious when they said they plan to cut legal expenses.) The diagnostic report allows individuals and physicians to develop personalized healthcare plans to help reduce risk, including lifestyle changes (eating healthy, losing weight, etc.), periodic screenings to catch problems early, and in some cases, taking preventive medicines, e.g., tamoxifen, raloxifene or anastrozole for women with BRCA mutation. I believe that NVTA is currently the market leader in the predictive genetics screening market. NVTA has, since its inception in 2010, pursued the ambitious goal of integrating genetic data into standard healthcare practice. It is a leading contributor to ClinVar, the National genome library funded by the Federal Government (The impact of NVTA's data contribution to ClinVar on its competitive position is complex and will be covered in a separate piece.) For now, it is enough to understand that NVTA's goal is to build a genetic network where patients' genetic information can help inform their medical decisions and empower them to take an active role in their care. In the long run, it hopes to reside at the center of this genomic ecosystem, managing and analyzing its data flow. Developing this ecosystem is an expensive commitment for the company. Here is an example. Suppose a physician requests a BRCA 1 test for a woman worried about getting breast cancer after her auntie developed the disease. For many insurance companies, more is needed to categorize the patient as having average risk (unless the auntie undergoes genetic profiling after her diagnosis, which, according to the United States Department of Health, is unlikely). Subsequently, the test will not be covered by insurance. NVTA will nonetheless process the physician's request. It will sequence not only the BRCA 1 gene but also BRCA 2 and 20,000 others, if not the entire patient's DNA, for future reference and to build its biobank. On top of that, it will likely not be paid. As a result, NVTA's expenses are higher than the industry average, and gross margins are poor (as shown in the table below). Data by YCharts The problem is, at this stage, the molecular diagnostic industry is in its early stages, primarily focusing on providing accurate genetic testing for patients while navigating a precarious regulatory environment playing catch up with the industry's rapid growth. Neither the genomic network nor the ecosystem NVTA is trying to create has yet materialized. Last week, the company released a report showing how it uses patient data and with whom. Based on the report, in 2021, the company shared genomic data with 31 biopharma companies on top of about a dozen academic institutions as part of its collaboration programs and its bioinformatics offering, which it records as "Other Revenue" on its financial statements. The report is a welcomed development in the industry, constituting a step towards more transparency in genomic data-sharing as the industry strives to establish and maintain trust among all stakeholders involved in healthcare, including patients and their families. It also provides a glimpse of how other companies treat their customers' data, further fuelling the debate around the ethical use of such data in medicine. During the Q3 earnings call, NVTA's CEO made the following comment on NVTA's bioinformatics business: While currently a small part of our total revenue, our data segment is a high-growth, high-margin, and scalable business, and there are more opportunities in our pipeline. Ken Knight, Q3 Earnings Call

Seeking Alpha • Nov 15

Invitae: This Turnaround Could Be Painful

Summary Invitae Corporation has one chance to leverage itself into profitability in the next 12 - 18 months. The cash balance is barely enough to cover the company's cash burn, even if it achieves its 2023, leaving little room for error. Executing the "realignment plan" must be flawless to create meaningful value for shareholders. Investment Thesis Invitae Corporation (NVTA) has one chance to leverage itself into profitability in the next 12 months. The market, which has long been its primary funding source, is unlikely to recover any time soon. As long as interest rates remain high and the stock market continues to trade at depressed levels, there is limited upside for Invitae unless it becomes a self-funding enterprise. At this point, earnings visibility remains low, providing little confidence in the ticker. The short squeeze and "tactical opportunity" discussed in the previous article have now played themselves out. In my view, Invitae Corporation shares will continue to trade sideways, offering little value to investors. A rating upgrade is conditional on the company demonstrating meaningful progress in its turnaround efforts and reducing its cash burn rate. Such actions would unlock additional value for existing shareholders. On the other hand, a rating downgrade is likely if the company fails to deliver on its turnaround plans or if it becomes dependent on dilutive sources for future financing. Third-Quarter Results NVTA reported topline sales of $133 million in Q3, up $19 million (17%) year-over-year, driven by a 9% increase in testing samples (324,000 units vs. 296,000 a year ago) and an increase in average selling prices ($398 per test vs. $377 per test a year ago) due to variances in payor and product mix (different payors are charged differently). These are solid numbers under the circumstances, especially given the July 2022 cliff, when management announced a "realignment plan," which saw a leadership change, layoffs, and discontinuation of certain businesses and products. Gross margins were suppressed this quarter, down significantly to 12.4% from 23.3% a year ago due to a mix of cash and non-cash extraordinary expenditures, namely an inventory write-down of its shutdown business segments, summing to $16 million in aggregate and $14 million in amortization expense. Excluding these items, the gross margin would have been up to 46%, compared to 35% a year ago. Most restructuring expenses, however, were recorded as operating expenses, namely severance packages for the 1000 or so employees made redundant in the past few months, as discussed in the previous article. Employee severance cost the company $58 million in Q3, in addition to $49 million in asset disposals (other than inventory disposals), such as equipment and building lease terminations. Shares rebounded on Q3 results, perhaps due to a short squeeze (short interest is 19%), but what is certain is that earnings were less than Wall Street expected. The $128 million operating cash loss is painful and raises total cash burn to nearly half a billion dollars this year. What remains in the company's coffers is $586 million in cash, cash equivalents, and marketable securities, leaving little room for errors in management's turnaround plan and cash burn projections (between $325 million cash burn reduction target and $245, representing realized annual run rate based on Q3 results), especially given that management expects an additional $170 million in restructuring expenses in the next 12 months, on top of operating expenses. Thus, dilution risk remains high. From experience, turnaround plans can be tricky, and in my view, execution risk remains high. The reduction in cash burn to $108 million represents an annualized run-rate reduction of approximately $245 million from Q1 and reinforces that we are on track to deliver the $326 million in cash burn reduction fully realized in 2023. - Ken Knight, Q3 conference call. Market Position NVTA has a unique market position, with strong brand recognition, supported by strong relationships with commercial insurance payors. The company is one of the first gene testing labs to enter the UnitedHealth provider network. For most of NVTA's peers, the commercialization process starts with Medicare, not insurance companies. NVTA, however, started selling its products before Key Opinion Leaders "KOLs" adopted gene diagnostics in the standard-of-care guidelines, as mirrored in its negative gross margins in 2013 -2016. The company's entrepreneurial spirit, combined with its commitment to democratizing the gene testing market through a low-cost, high-volume model, attracted the likes of SoftBank and Ark Invest, but now, with a solid alternative in the bond market, NVTA isn't attractive anymore. The company's focus on hereditary cancer risk screening, with established clinical utility, allowed it to quickly penetrate the market with minimal investment in clinical validity and trial studies. When NVTA started selling its BRCA1 and BRCA2 screening tests, the medical community already understood the connection between these two genes and the risks of breast and ovarian cancers. In recent years, NVTA did ramp up its R&D, namely for its Minimal Residual Disease market, but the expense account also includes activities tied to its customer accounts. This, from my understanding of management's comments, limits its ability to reduce total expenses through R&D cost reduction initiatives.

Seeking Alpha • Nov 08

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Invitae press release (NYSE:NVTA): Q3 GAAP EPS of -$1.27 misses by $0.43. Revenue of $133.54M (+16.7% Y/Y) beats by $2.16M. GAAP gross margin was 12.4%. Non-GAAP gross margin was 45.9% as compared with 40.1% in the second quarter of 2022 and 35.6% in the third quarter of 2021 Cash, cash equivalents, restricted cash and marketable securities of $596 million as of quarter end. Outlook: The company expects a low double-digit growth rate for its full year 2022 revenue over 2021. Non-GAAP gross margins are expected to be in the range of 42-43% for full year 2022. Invitae is reducing its full year 2022 cash burn guidance to $585-625 million, an improvement from its previous guidance of $600-650 million. This guidance includes cash to be used for realignment activities and severance of up to $75 million in 2022, which remained unchanged from the previous estimate.

Seeking Alpha • Sep 22

Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved

Summary Invitae is a genetic testing specialist with a suite of products targeting oncology, women's health, and other diseases. NVTA stock traded as high as $55 in January 2021, but today it is worth Losses of >$750m in 2021 and debt of nearly $2bn are the reasons for the bear run on Invitae stock. Under a new CEO, Invitae is culling staff and promising cost savings of >$300m, but it may not be enough. A $2.3bn goodwill write down and promise of a strategic review briefly revived NVTA stock price, but investors expecting an instant return on new initiatives may be disappointed. Investment Thesis Invitae Corp (NVTA) is a business that offers, in its own words: Offers high-quality, comprehensive, affordable genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions and rare diseases. (Source: 10-K submission 2021). Invitae has grown revenues in every year since 2013, from just $1.6m in that year, to $444m in 2021 - which represented a 63% year-on-year increase. That is the good news - the bad is that Invitae's share price, which had grown from $4.70 in early 2018, to $50 in January 2021, now trades at a value of $2.80 - down 94% in a little over 18 months. The underlying issue is easy to point to - as revenues grew, losses mounted, as illustrated by the table below. Invitae income statement 2012 - present day. (Seeking Alpha) Source: Seeking Alpha. Invitae may have delivered revenues of $272m in 2020, up 28%, but operating losses increased by 145%, to $598m. Revenues may have increased again in 2021, to $444m, but net losses increased by a further 30%, to $775m. Clearly, such a pattern is unsustainable, and Invitae has begun to take action. Kenneth Knight, who joined the company as Chief Operating Officer ("COO") in 2020 from Amazon - where he was Vice President of Transportation Services - was appointed CEO in July, replacing Sean George, Ph.D. who was in the role for five years, and now joins the Board of Directors. Knight's first task is to oversee a major "Strategic Business Realignment", designed to deliver $326m in non-GAAP annualised cost savings by 2023, which will involve ditching non-core operations and refocusing on "the portfolio of businesses that generate sustainable margins and deliver returns to fuel future investment", Invitae's words. ~1,000 employees at the company will also be sacrificed. When reporting Q2'22 earnings - with top line revenues of $136.6m, up 17.5% year-on-year - Invitae declared a net loss for the quarter of an astonishing $2.5bn, which included, according to a press release: A complete writedown of goodwill of $2.3 billion, which was a result of a significant, sustained decline in the stock price and related market capitalization and a lower than expected financial performance. Invitae also reported a cash position of $737m, and guided for FY22 revenues to be up by a low double digit percentage amount year-on-year - somewhere around the $500-$600m mark, perhaps - and for cash burn to be $600-$650m, including $75m set aside for "realignment activities and severance". When details of the Q2'22 earnings and restructuring plans were announced around 9th August, Invitae's share price briefly traded as high as $9 per share, before quickly sinking back <$3. It certainly seems as though the market had placed far too much trust in Invitae's ability to grow revenues, and not paid enough attention to its spiraling costs, and increasing debt - total liabilities currently stand at $1.9bn, including $1.46bn of convertible notes, a large tranche of which falls due in 2024. With Invitae's current market cap valuation being $652m, the question for investors to answer is whether the restructuring plan can work, and in the remainder of this post I will attempt to provide some additional colour on that by discussing Invitae's business plan, the details of the restructuring plan, markets and competition, and financial considerations. First of all, let's begin with a key and fundamental question. Is There A (Large Enough) Market For Invitae's Products? Growth without profit can sometimes be justified if the market opportunity is large enough - think of a company such as DexCom (DXCM), for example, which supplies glucose monitoring devices to diabetics, and swallowed a $186m loss in 2018, in order to ramp up manufacturing and reach more customers. That strategy has proven successful - DexCom is profitable and growing sales - but with >1m Type 1 diabetics and 21m Type diabetics in the US alone, the market opportunity was secure provided the product was good enough. In Invitae's case, the genetic testing market is estimated to be similar in size to the glucose monitoring market - both are apparently valued at ~$15bn, and expected to reach ~$30bn in size by 2030. Similar to DexCom and its continuous glucose monitoring devices ("CGMs"), patients who wish to use a genetic testing service must ask their physician to make the application on their behalf. Invitae says (in its Q2'22 10Q submission) that the company was founded on four key principles, as follows: Patients should own and control their own genetic information; Healthcare professionals are fundamental in ordering and interpreting genetic information; Driving down the price of genetic information will increase its clinical and personal utility; and Genetic information is more valuable when shared. The following diagram put together by the company demonstrates how it expects to grow in its markets. Invitae strategy for growth. (Invitae 10Q Q222) Source: company 10Q submission Q222. Competition is fairly intense in Invitae's markets however - the company lists its competition in its annual report as follows: Ambry Genetics, a subsidiary of Konica Minolta Inc.; Athena Diagnostics and Blueprint Genetics, subsidiaries of Quest Diagnostics Incorporated; Baylor-Miraca Genetics Laboratories; Caris Life Sciences, Inc.; Centogene AG; Color Genomics, Inc.; Connective Tissue Gene Test LLC, a subsidiary of Health Network Laboratories, L.P.; Cooper Surgical, Inc.; Emory Genetics Laboratory, a subsidiary of Eurofins Scientific; Foundation Medicine, a subsidiary of Roche Holding AG; Fulgent Genetics, Inc.; Guardant Health, Inc.; Integrated Genetics, Sequenom Inc., Correlagen Diagnostics, Inc., and MNG Laboratories, subsidiaries of Laboratory Corporation of America Holdings; Myriad Genetics, Inc.; Natera, Inc.; Perkin Elmer, Inc.; and Sema4 Genomics; as well as other commercial and academic labs. In addition, there are a large number of new entrants into the market for genetic information ranging from informatics and analysis pipeline developers to focused, integrated providers of genetic tools and services for health and wellness, including Illumina, Inc. which is also one of our suppliers. Compare that to DexCom, for example, which has only two competitors of note - Abbott Laboratories (ABT), and Medtronic (MDT). Invitae's range from startups to major pharmaceuticals, and to make matters worse, use cases around genetic testing are still not entirely clear. The industry arguably trades more on its potential than its fundamentals. To use the DexCom example once again, users of DexCom products can measure a positive outcome by a reduction in the number of hypo-glycemic and hyper-glycemic incidents, and the added convenience of not having to use fingerpricking devices. What does success look like for a Invitae customer? On its Q2'22 earnings call Invitae CEO Knight cited the example of the National Comprehensive Cancer Network ("NCCN") releasing new guidelines on colorectal cancer ("CRC"), endorsing universal germline genetic testing for all patients. Knight insisted that this decision was influenced by studies conducted by Invitae, and would lead to a doubling of the germline genetic testing population for CRC. Next, the company plans to target breast, prostate and lung cancer - far larger markets. Knight added that germline and somatic information - also supplied by Invitae - yields "earlier diagnosis, more actionable results, ongoing monitoring and potentially better outcomes", and that this is being continually proven in studies. Another attractive use case, is patient specific ctDNA detection for which can help patients detect biomarkers or understand if a treatment is working or not. Invitae has also developed a patient chat tool, known as Gia, to provide data collection services and translate them into actionable insights. Via a partnership with Worldwide Clinical Trials Incorporated the two companies have collected data from over two million patients. This type of data driven service may have a big role to play in Invitae's business model going forward, although in the near term, it may not have the impact the company hopes. The reason for this, as with the failure of telemedicine to catch on, is that patients are not receptive to it. Ultimately, I would conclude that there is a large enough market for a company like Invitae to be successful, even amongst so many other companies developing similar product suites. Much depends on which companies Invitae may be able to form relationships with - Illumina for example, is a genetic sequencing giant that can afford to bide its time and wait for its products to mature and become better suited to its target market, and Invitae needs to find more partners with deep pockets. That's clear because in 2021, for example, Invitae spent ~$1.4bn to earn $444m, yet despite its success with the CRC testing win, it's hard to think of an Invitae product that is unique, or indispensable. That needs to change, and quickly. Can Invitae Handle Its Debt Obligations? One of the problems Invitae has is that it is going to have to find ways to make its products more relevant and essential whilst slashing its R&D budget at the same time owing to the debt obligations the company must meet in 2024. CEO Knight mounted a defence of the company's strategy on the Q2'22 earnings call: There's going to be material impact to our R&D as a result of this now. At the same time, we were -- we feel we were really intentional and pretty darn smart about how we went about this. We looked at the business opportunity, the ability to serve our patients and clients, and we try to do this holistically. It wasn't just a kind of we didn't just make it up at the last minute. We really worked on this thoughtfully over a period of weeks, months. And we feel really good about the fact that we targeted the right businesses for us to exit.

Seeking Alpha • Aug 17

Why Invitae Corporation Could Underperform

Direct-to-consumer genetic testing via online platforms arouses some skepticism but appears to be a profitable venture in the US anyway. Invitae Corporation could benefit from rising public awareness of direct-to-consumer genetic testing, but the company must streamline activities. Due to the macroeconomic challenges, the coming quarters will be a very tough test for the company. The World of "Prevention is Better than Cure" Online Health Companies: Some Skepticism Is Normal The internet is undoubtedly the first place many people look for answers, especially when it concerns their physical health. Whether to dispel doubt, satisfy a curiosity or shake off fears, the internet is the first place to look. When it comes to personal health, prevention is better than cure [commonly attributed to the Dutch philosopher Desiderius Erasmus around year 1500]. A sacred principle on which many healthcare companies have built their business model, and all they need to operate is just a website that attracts customer demand. But to prevent the occurrence of pathologies, a healthy lifestyle is not the only thing people can do, because the right behavior can now be supplemented with early knowledge of a person's genetic predisposition to the risk of developing the pathologies. In other words, to find out if one is a carrier of genes commonly associated with certain pathologies, there are specific genetic tests that can be performed to cover the need for knowledge. Therefore, these "prevention is better than cure" online health companies found an interesting opportunity to offer genetic testing at relatively low prices, the results of which can also be viewed online, and with the possibility of even getting indicative information from a specialist. Of course, the cost of a genetic test depends on the scope of the diagnosis and research, but in general genetic testing can be very expensive, even up to a few thousand dollars. So frankly, the possibility of ordering a genetic test online to see if someone could develop a serious disease raises some skepticism, other than the fact that such activity could pose a risk of irrational behavior for the interpretation of the results. Nevertheless, this type of market in which genetic testing kits are sold directly to consumers online appears to be developing strongly. What is Invitae Corporation's Role in Diagnostics and Research? In the universe of US-listed medical genetics stocks engaged in diagnostics and research, Invitae Corporation (NVTA) stands out from a multitude of operators. The company is distinguished by the significant volume of its shares that are traded daily, which could mean that traders are quite interested in this stock. On Aug. 16, Invitae Corporation had exchanged 30.8 million shares during trading hours ranking second in the Diagnostics & Research stocks' ranking. T2 Biosystems, Inc. (TTOO), ranked first with 100.5 million shares traded, while Bionano Genomics, Inc. (BNGO) was in the third position with 12.2 million shares exchanged. The data was extracted from Finviz.com's stock screener after sorting the diagnostics and research industry by volume. Invitae Corporation, based in San Francisco, California, says it plans to integrate genetic information into mainstream medicine as it aims to improve healthcare for people in North America. Whether the person wants to have a screening test for cancer, cardiovascular disease, some hereditary diseases or personal feedback from pharmaceutical treatments, Invitae's website has test kits priced between $250 and $350, plus certain charges but excluding shipping costs. To submit an online request for a test, the order is placed by a doctor. Then a saliva sample can be given from home. The results are made available on the website user account and can be shared with the doctor. If the Invitae test result is positive, the order entitles the purchaser to a discount on the price. The consumer can also request an interview with a genetic counselor without paying any additional cost. The company states that the purpose of these tests is not to diagnose either a disease or a medical condition. Furthermore, the company says her tests are not medical advice. Invitae Corporation's Market Outlook Invitae Corporation operates in a rapidly growing market. Global Market Insights predicts that the direct-to-consumer genetic testing market powered by online platforms will grow significantly over the next few years, globally exceeding $4 billion in 2028. With a market share of approximately 40% of the total global market, the North American market is expected to continue to be the major contributor to global growth for three main reasons: a greater public awareness in the US and Canada of direct-to-consumer genetic testing rising Internet usage in the most populous regions of the US and Canada the willingness of North American watchdogs to streamline regulations for the direct-to-consumer genetic testing industry in certain cases. These factors will fuel the market growth as they will stimulate the demand for direct-to-consumer genetic testing. However, the market is far from easy given the sheer number of competitors and because the more aggressive competitors continue to bring technological innovations into their growth strategies. Invitae Corporation could do the same to expand the future of its genetic testing, but first the company must solve the problem of spending more money than it can earn. The Company's Realignment Plan Amid Uncertain Business Outlook The company recently informed shareholders of its next strategy, called the Corporate Realignment Plan, through which Invitae Corporation plans to reverse the relationship between cash outflows and cash inflows as the company is currently burning resources. By taking this action, Invitae Corporation believes it can save up to $326 million in annual costs in the next few quarters to 2023, which will be implemented in part through reductions in personnel costs and other non-essential costs. In addition, the company estimates that it will have approximately 26 months to continue being able to meet its various supplier and financial obligations.

Seeking Alpha • Aug 09

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Invitae (NYSE:NVTA) has reaffirmed its 2022 financial guidance as the medical genetics company's Q2 2022 results beat on both the top and bottom lines. Invitae (NVTA), however, swung to a quarterly loss of ~$2.5B (-$10.87 per share, diluted) from net income of $133.8M ($0.53 per share) in the year-ago period. The reason for the swing was a $2.3B asset impairment charge in Q2. That caused total cost and expenses to skyrocket. Revenue of $136.6M was a ~17% year-over-year increase. Regarding guidance, Invitae (NVTA) expects a low double-digit growth rate for its full year 2022 revenue compared to 2021. Over the longer term, the growth rate is expected to be 15%-25% after 2023. Read why Seeking Alpha contributor Bill Maurer is bearish on the stock.

Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Historische Aktienkurse
Aktueller Aktienkurs	US$0.0004
52-Wochen-Hoch	US$1.25
52-Wochen-Tief	US$0.000001
Beta	2.8
1 Monat Veränderung	-42.86%
3 Monate Veränderung	-76.47%
1 Jahr Veränderung	-99.97%
3 Jahre Veränderung	-100.00%
5 Jahre Veränderung	-100.00%
Veränderung seit IPO	-100.00%

	NVTA.Q	US Healthcare	US Markt
7D	0%	-0.4%	1.0%
1Y	-100.0%	16.3%	28.7%

NVTA.Q volatility
NVTA.Q Average Weekly Movement	642.7%
Healthcare Industry Average Movement	7.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

NVTA.Q grundlegende Statistiken
Marktanteil	US$114.60k
Gewinn(TTM)	-US$1.44b
Umsatz(TTM)	US$481.58m

NVTA.Q Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$481.58m
Kosten der Einnahmen	US$350.95m
Bruttogewinn	US$130.64m
Sonstige Ausgaben	US$1.57b
Gewinn	-US$1.44b

Gewinn per Aktie (EPS)	-5.03
Bruttomarge	27.13%
Nettogewinnspanne	-299.14%
Schulden/Eigenkapital-Verhältnis	-124.7%

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/08/05 19:33
Aktienkurs zum Tagesende	2024/08/02 00:00
Gewinne	2023/09/30
Jährliche Einnahmen	2022/12/31

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

Analyst	Einrichtung
Raymond Myers	Benchmark Company
Steven Wardell	Chardan Capital Markets, LLC
Matthew Sykes	Goldman Sachs

Invitae (NVTA.Q) Aktienübersicht

Risikoanalyse

Invitae Corporation Wettbewerber

First Choice Healthcare Solutions

ETAO International

Medivolve

Dogecoin Cash

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Invitae Corporation Filed for Bankruptcy

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

New minor risk - Market cap size

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Price target decreased by 11% to US$1.31

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Consensus EPS estimates fall by 119%

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Price target decreased by 14% to US$1.58

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Price target decreased by 13% to US$1.70

Consensus EPS estimates fall by 34%

Invitae Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 8.2% to US$1.87

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae: Revenue Troubles Build

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Is Treading In Competitive Waters

Invitae Corporation Announces Executive Changes

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

Consensus EPS estimates fall by 19%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 10.0% to US$2.26

Full year 2022 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Price target decreased by 7.4% to US$2.51

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Invitae: What Happened At The JP Morgan Health Conference

Invitae guides Q4 revenue above estimates

Director recently sold US$115k worth of stock

Invitae Likely Hasn't Reached The Bottom Yet

Consensus forecasts updated

Invitae: This Turnaround Could Be Painful

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Price target decreased to US$2.71

Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved

Why Invitae Corporation Could Underperform

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aktionärsrenditen

Preisvolatilität